Co-founder Fred Ramsdell, Ph.D., to retire from Chief Scientific Officer position September 29, 2023 07:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif. & SEATTLE – Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointments of Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, … Continue reading Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer